Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$11.04 -6.0%	$14.01	$7.05 ▼ $17.15	$308.18M	0.37	58,543 shs	98,440 shs
CMPS COMPASS Pathways	$4.30 +10.8%	$3.95	$2.25 ▼ $8.54	$363.02M	2.12	1.31 million shs	4.57 million shs
GOSS Gossamer Bio	$1.70 -0.6%	$1.27	$0.66 ▼ $1.89	$388.69M	1.86	1.47 million shs	3.18 million shs
IVVD Invivyd	$0.75 +3.9%	$0.79	$0.35 ▼ $2.74	$86.58M	0.52	4.56 million shs	835,948 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-0.09%	-14.87%	-23.96%	-14.62%	+21.03%
CMPS COMPASS Pathways	-1.27%	+4.30%	-13.39%	+23.96%	-47.99%
GOSS Gossamer Bio	+3.01%	+25.74%	+37.90%	+103.57%	+56.88%
IVVD Invivyd	+5.07%	-3.18%	-0.70%	+41.51%	-42.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.6851 of 5 stars	3.6	1.0	0.0	2.8	0.8	0.0
CMPS COMPASS Pathways	1.8352 of 5 stars	3.4	1.0	0.0	2.5	0.8	0.6
GOSS Gossamer Bio	3.8036 of 5 stars	3.5	1.0	4.7	2.6	1.7	0.0
IVVD Invivyd	3.7022 of 5 stars	3.6	4.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.20	Buy	$23.83	115.88% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	295.35% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	385.29% Upside
IVVD Invivyd	3.25	Buy	$5.85	680.00% Upside

Current Analyst Ratings Breakdown

Latest IVVD, BNTC, GOSS, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	3,622.50	N/A	N/A	$4.68 per share	2.36
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GOSS Gossamer Bio	$114.70M	3.37	N/A	N/A	$0.13 per share	13.08
IVVD Invivyd	$25.38M	3.54	N/A	N/A	$0.56 per share	1.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.82	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)

Latest IVVD, BNTC, GOSS, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/7/2025	Q2 2025	CMPS COMPASS Pathways	-$0.41	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
GOSS Gossamer Bio	6.70	5.71	5.71
IVVD Invivyd	N/A	1.53	1.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
GOSS Gossamer Bio	81.23%
IVVD Invivyd	70.36%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
GOSS Gossamer Bio	6.70%
IVVD Invivyd	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable

IVVD, BNTC, GOSS, and CMPS Headlines

Recent News About These Companies

Invivyd (NASDAQ:IVVD) Trading 5.1% Higher - Here's Why

July 18 at 3:37 AM | americanbankingnews.com

Invivyd (NASDAQ:IVVD) Trading Up 5.1% - Here's Why

July 18 at 3:36 AM | marketbeat.com

Invivyd, Inc. (IVVD) stock price, news, quote & history - Yahoo Finance

July 8, 2025 | nz.finance.yahoo.com

Invivyd, Inc. Forms SPEAR Study Group to Investigate PEMGARDA® Therapy for Long COVID and Post-Vaccination Syndrome

July 2, 2025 | quiverquant.comQ

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

July 2, 2025 | globenewswire.com

Invivyd's (IVVD) Buy Rating Reaffirmed at HC Wainwright

June 26, 2025 | marketbeat.com

D. Boral Capital Reaffirms "Buy" Rating for Invivyd (NASDAQ:IVVD)

June 26, 2025 | marketbeat.com

Invivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and Treatment

June 26, 2025 | quiverquant.comQ

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

June 26, 2025 | globenewswire.com

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

May 29, 2025 | msn.com

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025 | globenewswire.com

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network®

May 23, 2025 | bakersfield.comB

Invivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell Lymphomas

May 23, 2025 | quiverquant.comQ

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025 | globenewswire.com

Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy

May 23, 2025 | nasdaq.com

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025 | globenewswire.com

Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss

May 16, 2025 | investing.com

Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

May 16, 2025 | finance.yahoo.com

Invivyd Reports Q1 2025 Financial Results and Outlook

May 15, 2025 | tipranks.com

INVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and More

May 15, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, BNTC, GOSS, and CMPS Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$11.06 +0.02 (+0.14%)

As of 07:22 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.30 +0.42 (+10.82%)

Closing price 04:00 PM Eastern

Extended Trading

$4.31 +0.01 (+0.23%)

As of 07:46 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Gossamer Bio NASDAQ:GOSS

$1.70 -0.01 (-0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 06:33 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Invivyd NASDAQ:IVVD

$0.75 +0.03 (+3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-1.73%)

As of 07:29 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time